Chris Cooley – Stephens & Co.

Stephens & Co.

A Stephens & Co. analyst with 12 tracked ratings across 12 distinct tickers has a 41.7% success rate on the captured sample, covering two sources.

Aggregated from multiple market-data sources

Total ratings

Tickers covered

Sources

Aggregated

Latest rating

4 years ago

2022-04-01 00:00:00+00

Track record

Aggregated

42% success rate

Bullish: 0
Hold: 0
Bearish: 0

Aggregated

Not available

Bullish: 1
Hold: 0
Bearish: 0

Recent ratings

Ticker	Date	Rating	Price target	Source
PLSE	2022-04-01	buy	$12.00	Aggregated
ANIK	2022-03-09	unknown	-	Aggregated
COOCOOPER COMPANIES, INC.	2022-03-07	unknown	$500.00	Aggregated
SDC-	2022-03-02	unknown	$3.00	Aggregated
ALCALCON INC. - REGISTERED SHARES	2022-01-18	unknown	$86.00	Aggregated
ANIKANIKA THERAPEUTICS INC.	2021-11-16	unknown	$55.00	Aggregated
ESTAESTABLISHMENT LABS HOLDINGS INC	2021-11-10	unknown	$90.00	Aggregated
STESTERIS PLC	2021-11-04	unknown	$270.00	Aggregated
GKOSGLAUKOS CORPORATION	2021-11-03	unknown	$68.00	Aggregated
AVNS	2021-08-04	unknown	$45.00	Aggregated
AVNSAVANOS MEDICAL INC	2021-08-04	unknown	$45.00	Aggregated
PLSEPULSE BIOSCIENCES INC	2021-07-27	unknown	$28.00	Aggregated

Tickers covered(12)

Ticker	Ratings	Last rating	Sources
PLSE	1	2022-04-01	Aggregated
ANIK	1	2022-03-09	Aggregated
COOCOOPER COMPANIES, INC.	1	2022-03-07	Aggregated
SDC-	1	2022-03-02	Aggregated
ALCALCON INC. - REGISTERED SHARES	1	2022-01-18	Aggregated
ANIKANIKA THERAPEUTICS INC.	1	2021-11-16	Aggregated
ESTAESTABLISHMENT LABS HOLDINGS INC	1	2021-11-10	Aggregated
STESTERIS PLC	1	2021-11-04	Aggregated
GKOSGLAUKOS CORPORATION	1	2021-11-03	Aggregated
AVNS	1	2021-08-04	Aggregated
AVNSAVANOS MEDICAL INC	1	2021-08-04	Aggregated
PLSEPULSE BIOSCIENCES INC	1	2021-07-27	Aggregated

Methodology differs by source. Track records are aggregated from multiple sources; scoring methodology and scales differ by source and values are not directly comparable. Coverage is sourced from publicly-aggregated analyst activity. Past performance does not guarantee future results. Not investment advice.